News

  • 31 October 2017

    Sonendo®, Inc., announced today it has been named a winner of the 2017 OCTANe High Tech Innovation Awards. Sonendo, Inc. received the award for the Best Healthcare Company at OCTANe’s 24th annual award ceremony, held on October 12. 

  • 31 October 2017

    Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, today announces that overall survival data from two Phase I clinical trials of its wholly owned, lead programme, IMCgp100, in metastatic uveal melanoma will be presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting. This year’s SITC is taking place 8 – 12 November, 2017, at the Gaylord National Resort & Convention Center in National Harbor, Maryland in USA. 

  • 24 October 2017

    Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, today announced that Prof. Florence Wong, University of Toronto, presented the findings of the MOSAIC study data at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®), held in Washington, DC.

  • 24 October 2017

    Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that the first patient has been dosed in the Company’s Phase 2b clinical trial of topical product candidate SNA-120 (pegcantratinib) in the treatment of pruritus, or itch, associated with psoriasis and in the treatment of psoriasis itself. SNA-120 is designed to selectively inhibit tropomyosin receptor kinase A, or TrkA, the high affinity receptor for nerve growth factor, or NGF, a known mediator of itch and neurogenic inflammation associated with psoriasis. This multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy, safety and tolerability of SNA-120 compared to vehicle in approximately 190 patients with at least moderate pruritus and mild-to-moderate psoriasis.

  • 23 October 2017

    Wilson Therapeutics (publ) today announced that the discussions with the U.S Food and Drug Administration (FDA) and the European Medicines Agency (EMA), regarding the study protocol for the single pivotal Phase 3 FOCuS trial for WTX101 in Wilson Disease, have been concluded successfully. Wilson Therapeutics will now complete the preparatory work to start the trial and expects to enroll the first patient in early 2018. WTX101 (bis-choline tetrathiomolybdate) is a first-in-class copper-protein-binding agent with a unique mechanism of action, under investigation as a novel therapy for Wilson Disease.